PMID- 15944777
OWN - NLM
STAT- MEDLINE
DCOM- 20050915
LR  - 20201222
IS  - 1021-335X (Print)
IS  - 1021-335X (Linking)
VI  - 14
IP  - 1
DP  - 2005 Jul
TI  - Flow cytometric analysis of circulating dendritic cell subsets and intracellular 
      cytokine production in advanced breast cancer patients.
PG  - 113-20
AB  - Patients with advanced cancer are known to have dysfunctions of the immune 
      system. Dendritic cells (DCs) are potent antigen-presenting cells that play a 
      crucial role in antitumor immune response. At least two peripheral blood DC 
      subsets have been described: myeloid-derived CD11c+CD123- DCs (DC1) and 
      lymphoid-derived CD11c-CD123+ DCs (DC2). Upon interaction with T cells, DC2 
      seemed to support the generation of a Th2 response, while DC1 predominantly prime 
      a Th1 response. Our study was aimed at investigating the number of circulating 
      DCs, and their subsets and functions in 32 patients with advanced breast cancer 
      that achieved an objective response after a standard-dose sequential chemotherapy 
      (CT), compared to 40 healthy controls. Circulating DC subsets and intracellular 
      cytokine production in CD4+ and CD8+ subsets were analyzed using a tri-color flow 
      cytometry assay. DC subsets were identified in peripheral blood, calculating 
      their percentage gated as lin- HLA-DR+ and using BDCA-1, BDCA-2 and BDCA-3 
      specific markers, as DC1 and DC2 according to expression of CD11c and CD123, 
      respectively. Intracellular cytokines were evaluated in CD4+(Th1 and Th2) and 
      CD8+ (Tc1 and Tc2) T lymphocytes. The mean percentage of BDCA-1+BDCA-2+BDCA-3 was 
      similar to that of DC1+DC2 (p=ns). The mean percentage of DCs and DC1/DC2 ratio 
      were slightly decreased before CT in cancer patients compared with healthy 
      controls (p=ns). After CT, the percent-age of DC1 further decreased (p=0.02). The 
      production of IFN-gamma (Th1 and Tc1) significantly decreased (p<0.03) while that 
      of IL-4 (Th2 and Tc2) increased (p=0.04), thus confirming a shift toward a Th2 
      CD4 and Tc2 CD8 phenotype and the predominance of type 2 DCs. Our results could 
      help clarify the mechanisms of the immune response or immune status of patients 
      with advanced breast cancer that undergo cytotoxic CT and contribute to improve 
      the selection of potential candidates for active immunotherapy trials.
FAU - Ferrari, Silvia
AU  - Ferrari S
AD  - Flow Cytometry and Cell Therapy Unit, Medical Oncology, IRCCS San Matteo 
      University Hospital, 2, P.le Golgi, 27100 Pavia, Italy. 
      flow.cytometry@smatteo.pv.it
FAU - Malugani, Fabio
AU  - Malugani F
FAU - Rovati, Bianca
AU  - Rovati B
FAU - Porta, Camillo
AU  - Porta C
FAU - Riccardi, Alberto
AU  - Riccardi A
FAU - Danova, Marco
AU  - Danova M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Oncol Rep
JT  - Oncology reports
JID - 9422756
RN  - 0 (CD11c Antigen)
RN  - 0 (Cytokines)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (IL3RA protein, human)
RN  - 0 (Interleukin-3 Receptor alpha Subunit)
RN  - 0 (Receptors, Interleukin-3)
RN  - 207137-56-2 (Interleukin-4)
RN  - 82115-62-6 (Interferon-gamma)
RN  - NI40JAQ945 (Tetradecanoylphorbol Acetate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Breast Neoplasms/*blood/drug therapy/metabolism
MH  - CD11c Antigen/analysis
MH  - CD4-Positive T-Lymphocytes/drug effects/metabolism
MH  - CD8-Positive T-Lymphocytes/drug effects/metabolism
MH  - Cell Lineage/drug effects/immunology
MH  - Cytokines/*metabolism
MH  - Dendritic Cells/cytology/drug effects/*immunology
MH  - Female
MH  - Flow Cytometry/*methods
MH  - HLA-DR Antigens/analysis
MH  - Humans
MH  - Interferon-gamma/metabolism
MH  - Interleukin-3 Receptor alpha Subunit
MH  - Interleukin-4/metabolism
MH  - Intracellular Space/drug effects/metabolism
MH  - Middle Aged
MH  - Receptors, Interleukin-3/analysis
MH  - Tetradecanoylphorbol Acetate/pharmacology
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2005/06/10 09:00
MHDA- 2005/09/16 09:00
CRDT- 2005/06/10 09:00
PHST- 2005/06/10 09:00 [pubmed]
PHST- 2005/09/16 09:00 [medline]
PHST- 2005/06/10 09:00 [entrez]
PST - ppublish
SO  - Oncol Rep. 2005 Jul;14(1):113-20.